Why Leading Sterilization Facilities Are Adding VHP to Their EtO Operations

Ethylene oxide sterilization is not going away. It sterilizes approximately half of all medical devices sold in the United States — more than 20 billion units annually — and despite years of regulatory pressure, the infrastructure that supports it remains deeply embedded in the medical supply chain. The EPA's March 2026 proposed reconsideration of its 2024 emission standards — which would relax, not tighten, the prior rule — confirms that EtO's role in the industry is more durable than many anticipated.

That durability is precisely why the most forward-thinking EtO facilities are adding VHP capability right now. Not because EtO is going away, but because a growing category of products cannot be optimally sterilized with EtO — and those products represent some of the fastest-growing segments in the medical device and life sciences markets.

The decision isn't EtO or VHP. It's EtO and VHP.

The Single-Technology Constraint

EtO is well-suited for a wide range of products: heat-sensitive devices, complex geometries, certain polymers, and densely packed product loads. It earned its dominant position through decades of validated performance across these applications.

What it is not suited for is an expanding class of products where residue, cycle time, or material sensitivity make EtO a poor fit. Combination products with drug coatings that degrade under EtO conditions. Cell therapy components where any trace of ethylene oxide residue is unacceptable. 3D-printed implants whose porous geometries trap residue and require extended aeration periods that change the economics of the process entirely.

These product categories are not niche. They are growing. And EtO facilities that cannot service them are turning away business — or watching manufacturers route those products elsewhere.

The Product Categories EtO Cannot Optimally Serve

The growth in biologics, advanced materials, and combination products is structural, not cyclical. Several specific categories represent concentrated opportunity for EtO facilities willing to add VHP capability:

Advanced biologics and cell therapy components — These materials require absolute zero residue. Ethylene oxide leaves trace residues that require extended aeration before product release, and published research has shown that EtO adducts with protein residues in biologics — including cysteine and methionine — even at residue levels within ISO limits. For cell-based therapies and biologics with residue-intolerant components, this is not a process constraint to be engineered around — it is a disqualifying characteristic.

3D-printed porous implants — The complex internal geometries created by additive manufacturing trap EtO gas in ways that complicate residue clearance and extend aeration requirements significantly. Research on sterilization of 3D-printed medical devices confirms that porous structures create extended desorption timelines that can compromise product release schedules. VHP, which decomposes completely to water and oxygen without requiring a separate aeration step, addresses this problem directly.

Combination products (drug + device) — Devices that incorporate pharmaceutical coatings, drug-eluting components, or biologics face material compatibility challenges with EtO that often cannot be resolved without compromising the drug component. Peer-reviewed studies on drug-eluting stent sterilization document measurable drug content loss attributable to the heat and humidity conditions of EtO cycles. The FDA's own guidance on combination product development notes that certain drug or biological product constituent parts may be altered or destroyed by terminal sterilization — a risk that must be assessed and resolved before regulatory submission.

Bioabsorbable implants requiring zero residue — For applications where implant-residue interaction is a concern — particularly in direct tissue contact applications — VHP's residue-free profile provides a technical advantage that simplifies both validation and regulatory submission.

These are not edge cases. They represent a meaningful and growing share of new product development pipelines in orthopedics, cardiovascular, regenerative medicine, and pharmaceutical combination products.

The "AND" Strategy

The framing of this decision matters. Adding VHP capability does not require retiring EtO capacity. It requires adding capacity — a second sterilization modality that handles product categories the first cannot.

The operational model is additive: EtO continues to process the product portfolio it serves well. VHP processes the categories where EtO is a poor fit. The facility gains the ability to serve a broader customer base, bid on product categories previously out of reach, and offer manufacturers a single-source solution for their entire device portfolio.

This is a revenue expansion story, not a cost reduction story. The EtO infrastructure is not redundant. It is complemented.

Consider the business case from the manufacturer's side: a device company developing a combination product cannot route that product through an EtO facility that cannot guarantee residue clearance or material compatibility. They will go elsewhere — to a contract sterilizer that offers VHP, or they will build the capability themselves. The EtO-only facility loses that customer permanently, not just for the current product but for every next-generation device in that manufacturer's pipeline.

The facilities adding VHP now are not hedging against EtO's decline. They are positioning to capture the product categories EtO cannot touch — categories that will represent a growing share of industry revenue over the next decade as the medical device pipeline shifts toward biologics, drug combinations, and advanced implant geometries.

The Regulatory Hedge

The March 2026 EPA proposed reconsideration is a useful data point, but it is not a stable equilibrium. The underlying tension between EtO's role in the medical device supply chain and its status as a known human carcinogen has not been resolved — it has been deferred. Regulatory direction has shifted multiple times over the past decade and will likely shift again.

The 2024 EPA final rule required more than 90% emission reductions. The 2026 reconsideration proposes to roll back portions of that standard. Neither outcome eliminates the underlying compliance obligation — the original 1994 NESHAP standards remain in place regardless of the reconsideration outcome, and community and legal pressure on EtO-intensive facilities has not diminished simply because the rulemaking pendulum has swung.

EtO facilities that have added VHP capability are not dependent on how that tension resolves. They have diversified their sterilization infrastructure in a way that reduces exposure to any single regulatory outcome. If future standards tighten, their VHP operations are already validated and running. If standards remain relaxed, their EtO operations continue unchanged.

The cost of building that optionality — adding a validated VHP system — is far lower than the cost of being forced to respond reactively to regulatory change. The facilities that add VHP under favorable conditions set the terms. Those that wait for regulatory pressure to force the decision will set the timeline on someone else's schedule.

SteriFlex: Designed for This Transition

PuroGen Laboratories has been developing and validating VHP sterilization systems since 1996. The SteriFlex platform — PuroGen's programmable VHP sterilization system — was designed from the beginning for the validation requirements of regulated industries: healthcare, medical devices, life sciences, tissue banking, and pharmaceutical manufacturing.

SteriFlex achieves SAL 10⁻⁶ terminal sterilization in cycles as short as 20 minutes. It operates with zero carbon footprint, leaves no residue (VHP decomposes to water and oxygen), and is non-destructive to the materials it processes. The system provides independent parametric control of VHP concentration, temperature, humidity, and cycle timing — allowing each product type to be validated against its specific material and packaging requirements without compromising the cycle parameters optimized for other products running through the same chamber.

That programmability is the operational key for multi-product facilities. A single SteriFlex system can run validated cycles for a bioabsorbable implant, a combination device, and a cell therapy component — each against its own validated parameter set, each with its own documentation trail. A fixed-cycle system cannot do this. The product diversity that characterizes modern contract sterilization demands programmable parametric control as a prerequisite, not a feature.

For EtO facilities evaluating VHP addition, SteriFlex is designed to operate alongside existing sterilization infrastructure. It does not require replacing what works. It requires adding what the current system cannot do.

The Strategic Window

The product categories that benefit most from VHP — advanced biologics, combination products, 3D-printed implants — are not waiting for sterilization infrastructure to catch up. They are entering development pipelines now and reaching commercialization on defined timelines. The manufacturers behind them are making sterilization partner decisions as they approach design freeze and pre-submission planning — decisions that determine which facilities they work with for the life of those products.

This is not an abstract future scenario. The 3D-printed medical implant market is valued at approximately $1.4 billion in 2026 and projected to reach $4.8 billion by 2033 at a CAGR over 19%. The cell therapy market is expanding faster than its infrastructure. Combination product submissions to FDA are growing annually. These are measurable, documented market trajectories — and the manufacturers driving them are asking which sterilization facilities have validated VHP capability before they send requests for quotation.

The window to establish VHP capability on a deliberate timeline — rather than a reactive one — has a specific character: it is open now and it will close. Not because a regulatory deadline will shut it, but because early-mover contract sterilizers will have established relationships with the key manufacturers in these categories. Once a device company's sterilization partner has been chosen, the incumbency advantage is substantial. The device manufacturer's product is validated against that facility's specific process. Switching has a full revalidation cost. The EtO-only facility that begins VHP capability after those relationships are established will face a harder competitive entry than the one that is already in the customer's validation program.

The facilities adding VHP capability now are not hedging against uncertainty. They are making a deliberate decision to be in the conversation for product categories that will define the next decade of contract sterilization revenue. That decision, made now, produces a different competitive position than the same decision made two years from now.

Frequently Asked Questions

**Can I add VHP sterilization to an existing EtO facility without disrupting current operations?**

Yes. VHP sterilization systems are modular and designed to operate independently alongside existing EtO infrastructure — separate chambers, independent scheduling, no shared process equipment. There is no cross-contamination risk between EtO and VHP chambers. The two processes can share general facility infrastructure, cleanroom personnel, and quality systems with targeted cross-training. The facility assessment phase identifies the specific space, utility connections, and HVAC requirements before equipment procurement. For most EtO facilities with available floor space, the VHP addition does not require displacement of existing operations.

**What is the difference between EtO and VHP sterilization for the products described here?**

Ethylene oxide sterilizes through alkylation — a chemical reaction with microbial DNA and proteins — and requires post-sterilization aeration (typically 12–72 hours) to remove toxic residues. For product categories with residue sensitivity — cell therapy components, combination products with biological constituents, bioabsorbables designed for tissue absorption — EtO residue clearance is either technically insufficient or economically prohibitive. Vaporized hydrogen peroxide sterilizes through gas-phase oxidation and decomposes completely to water and oxygen during the aeration phase. There are no toxic residues to clear. For the four product categories covered in this article, VHP's residue-free profile is not a preference — it is the technical requirement the product imposes.

**How long does validating VHP capability take for a facility already running validated EtO processes?**

VHP process validation — IQ/OQ/PQ per ISO 22441:2022 — requires 6–12 months from equipment procurement to a validated, submission-ready process. For facilities with experienced sterilization validation teams, existing quality systems under 21 CFR Part 820, and familiarity with ISO 11135 from EtO validation, the structural learning curve is low. The timeline is driven by the rigor required in process development and biological indicator qualification — which cannot be compressed — not by unfamiliarity with the quality system architecture.

**Is VHP recognized by FDA for device sterilization submissions, and what standard governs validation?**

Yes. In January 2024, FDA formally reclassified VHP sterilization to Established Category A — placing it alongside steam, EtO, dry heat, and irradiation as an established terminal sterilization method. ISO 22441:2022, recognized by FDA as a consensus standard in May 2023, provides the validation framework. A 510(k) or PMA sterility section for a VHP-sterilized device documents the validated process per ISO 22441 and cites VHP's Category A status — the same evidentiary structure as an EtO or steam submission. No additional method justification is required.

**What products are best suited for VHP sterilization in a contract setting?**

VHP is best suited for products where residue is technically unacceptable (cell therapy components, combination products with biological constituents), where materials are sensitive to EtO humidity and temperature conditions (drug coatings, bioabsorbable polymers), or where complex porous geometries make EtO residue clearance operationally difficult (3D-printed implants with engineered porosity). These are not niche categories — they represent the fastest-growing segments of the current medical device development pipeline. For a full technical breakdown of each category and the specific reasons EtO is suboptimal, see the companion piece [The Products Your EtO Facility Can't Sterilize — And How VHP Opens the Door](/insights/vhp-sterilization-product-categories).